We’re building a UK-wide site network of purpose-built sites dedicated to CNS and psychiatric trials and designed around people, not processes.

Because when every site in your network is purpose-built for CNS research and operated by people who see patients as humans, not data points, extraordinary results become the standard.

Our site network offers

  • Faster and more representative patient recruitment

  • Unmatched operational consistency​

  • Fast-tracked site selection, set up and trial initiation

  • Single point of contracting

  • Access to experienced investigators, doctors and central raters

Therapeutic expertise

Psychiatry

Depression, PTSD, Anxiety Disorders, Eating Disorders, Substance Use Disorders, ADHD, Autism Spectrum Disorder

CNS

Pain, Parkinson’s Disease, Alzheimer’s Disease, Dementia

Our Trial Sites in London

The prime location for psychiatry and CNS trials

1. Welbeck Street

Capacity: 3 treatment rooms

2. Baker Street

Capacity: 6 treatment rooms

Doncaster | In partnership with RDaSH NHS Foundation Trust

An NHS-embedded model designed with patient access, commercial timelines, and NHS infrastructure seamlessly built in.

Our Doncaster site is the UK’s first-ever NHS-private partnership focused on CNS and mental health research. Developed in collaboration with Rotherham Doncaster and South Humber NHS Foundation Trust (RDaSH), the site is embedded in NHS infrastructure while operated by Clerkenwell Health - combining the trust and reach of the NHS with the delivery strength of a specialised commercial trials provider.

Why Doncaster

Located in a region often underserved by clinical research, Doncaster provides a valuable opportunity to engage a diverse, non-London patient population - supporting research goals around inclusion and representation. The site also contributes to regional capacity building by revitalising unused NHS facilities and training local NHS staff in advanced research delivery.

Why NHS Partnership

By embedding trials within real-world NHS care settings, this model removes many of the traditional barriers in UK research - enabling faster start-up, smoother recruitment, and greater patient trust. Sponsors benefit from NHS alignment without operational complexity, supported by Clerkenwell’s full-service delivery model.

Capacity

The site features:

  • 8 dosing and screening rooms

  • Refreshed pharmacy with Schedule 1 capabilities

  • Licensed for controlled drug trials

  • Staffed in collaboration with local NHS clinicians

  • Linked to Clerkenwell’s central patient recruitment and quality infrastructure

Sites 4 and 5 are opening by the end of 2026.

  • 20m live within 1.5h of our trial sites 

  • 56% of Londoners don’t identify as White British 

  • >10 hospitals we’re currently able to recruit from 

  • Schedule 1-4 Home Office licensed pharmacy

  • 6 PIs, 10 doctors, >40 therapists and central raters

  • 15 CNS & psychiatry conditions we have worked across​

  • "Their fast site set-up, expertise and timely recruitment of patients have been evident throughout our ongoing [trials]. We are impressed by their high standards of professionalism and commitment to delivery..."

    Beckley Psytech

  • "Strong therapists and strong patient recruitment. Following the performance of your first site, having a second (and even more) would be a big help to accelerate the delivery of our trial."

    Transcend Therapeutics

Our Principal Investigators (PIs)

Combined experience of 75 years in 20+ indications

Dr Iain Jordan

Dr Iain Jordan

Psychiatry

20 years as Consultant Psychiatrist with past 10 years at ​Oxford University Hospital NHS FT. Also Hon. Sen. Lecturer at University of Oxford​.

Trial experience: 11 years​

Speciality: Psychosis, anxiety, trauma ​

Drugs: Psychedelics ​

Dr Conor Clerkin-Olive

Dr Conor Clerkin-Olive

CNS

Expertise in clinical drug development and phase I – IV studies as clinical research physician in Re:Cognition Health, Quotient Sciences and Protas.​

Trial experience: 6 years​

Speciality: Dementia, Migraine, Alzheimer’s

Drugs: Small and large molecules

Dr Paul Morrison

Dr Paul Morrison

Psychiatry

20 years experience in pharmacology & psychiatry. Hon. Sen. Lecturer at King’s College London. Designed numerous trials with >200 participants.​

Trial experience: 16 years​

Speciality: Psychosis, TRD, Addiction​

Drugs: Psychedelics, cannabinoids​

Dr Mallika Pullukoglu

Dr Mallika Punukollu

CNS & Psychiatry

Consultant Psychiatrist and Hon. Sen. Lecturer at Uni. of Glasgow, with 17 years experience in mental health. Led NHS and commercial trials as Sen. Researcher.

Trial experience: 11 years ​

Speciality: ADHD, ASD, Addiction, MDD​

Drugs: GABA agonists, psychotropic solutions, psychedelics, cannabinoids

Dr Babatunde Oyesile

Dr Babatunde Oyesile

CNS & Psychiatry

Principal, Chief, and National lead to 120 trials at leading CROs and hospitals in the last decade. Also medical monitoring expert​.

Trial experience: 14 years​

Speciality: Cardiovascular, pain, CNS​

Drugs: Migraine, Monoclonal antibodies, Bone health, Lipid-lowering, ARBs, Beta-agonists​

Dr Liliana Galindo Guarin

Dr Liliana Galindo Guarin

Psychiatry

Affil. Asst. Professor at University of Cambridge. Also Medical Leader in Psychosis at Cambridgeshire & Peterborough NHS FT​.

Trial experience: 12 years​

Speciality: Psychosis, PTSD, Insomnia​

Drugs: Cathinones, enzyme inhibitors, antipsychotics, psychedelics, cannabinoids​

3-10x

Faster recruitment compared to other sites 

2 weeks

Between sponsor greenlight and first patient screened

90%

Enrolled participant retention 

6

PIs with combined experience of 75 years in 20+ indications

Speak to our team ⟶

>50k

Vetted UK patient database

>1m

Patient records accessible via partnerships